Ito Yasuhiro, Yoshida Hiroshi, Tomoda Chisato, Uruno Takashi, Takamura Yuuki, Miya Akihiro, Kobayashi Kaoru, Matsuzuka Fumio, Kuma Kanji, Nakamura Yasushi, Kakudo Kennichi, Miyauchi Akira
Kuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe 650-0011, Japan.
Cancer Lett. 2005 Nov 18;229(2):291-7. doi: 10.1016/j.canlet.2005.06.040. Epub 2005 Aug 10.
Cdc25B and cdc25A phosphatases are prominent stimulators of cell cycle progression and have been suggested to play oncogenic roles. In this study, we immunohistochemically investigated the expression of these phosphatases in medullary thyroid carcinoma. Cdc25B was positive in 35.8% of cases examined. Its positivity was linked only to patient age. However, patients with cdc25B-positive tumors showed a significantly worse disease-free survival rate (P=0.0210) than those with cdc25B-negative tumors. Cdc25A was positive in only 17.2% of cases and was not related to clinicopathological parameters or prognosis. These findings suggest that cdc25B can be regarded as having prognostic significance and as a novel marker of biologically aggressive characteristics in this carcinoma.
